Hong-Shuo Sun

Hong-Shuo Sun

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2018 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
MBMei-Hua Bao
Mei-Hua Bao
VSVivian Szeto
Vivian Szeto
BYBurton B. Yang
Burton B. Yang
SZShu-Zhen Zhu
Shu-Zhen Zhu
HSHong-Shuo Sun
Hong-Shuo Sun
ZFZhong-Ping Feng
Zhong-Ping Feng
: Stroke is one of the leading causes of mortality and disability worldwide. Uncovering the cellular and molecular pathophysiological processes in stroke have been a top priority. Long non-coding (lnc) RNAs play critical roles in different kinds of diseases. In recent years, a bulk of aberrantly expressed lncRNAs have been screened out in ischemic stroke patients or ischemia insulted animals using new technologies such as RNA-seq, deep sequencing, and microarrays. Nine specific lncRNAs, antisense non-coding RNA in the INK4 locus (ANRIL), metastasis-associate lung adenocarcinoma transcript 1 (MALAT1), N1LR, maternally expressed gene 3 (MEG3), H19, CaMK2D-associated transcript 1 (C2dat1), Fos downstream transcript (FosDT), small nucleolar RNA host gene 14 (SNHG14), and taurine-upregulated gene 1 (TUG1), were found increased in cerebral ischemic animals and/or oxygen-glucose deprived (OGD) cells. These lncRNAs were suggested to promote cell apoptosis, angiogenesis, inflammation, and cell death. Our Gene Ontology (GO) enrichment analysis predicted that MEG3, H19, and MALAT1 might also be related to functions such as neurogenesis, angiogenesis, and inflammation through mechanisms of gene regulation (DNA transcription, RNA folding, methylation, and gene imprinting). This knowledge may provide a better understanding of the functions and mechanisms of lncRNAs in ischemic stroke. Further elucidating the functions and mechanisms of these lncRNAs in biological systems under normal and pathological conditions may lead to opportunities for identifying biomarkers and novel therapeutic targets of ischemic stroke.

19 April 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
WCWen-Liang Chen
Wen-Liang Chen
ABAndrew Barszczyk
Andrew Barszczyk
ETEkaterina Turlova
Ekaterina Turlova
MDMarielle Deurloo
Marielle Deurloo
BLBaosong Liu
Baosong Liu
HSHong-Shuo Sun
Hong-Shuo Sun
Inhibition of TRPM7 by carvacrol suppresses glioblastoma cell proliferation, migration and invasion

19 February 2015 in Molecular Brain
Verified
Journal Article
Open access
PDF file
WCWenliang Chen
Wenliang Chen
BXBaofeng Xu
Baofeng Xu
AXAijiao Xiao
Aijiao Xiao
LLLing Liu
Ling Liu
XFXiaoyan Fang
Xiaoyan Fang
HSHong-Shuo Sun
Hong-Shuo Sun
Our previous study found that suppression of TRPM7 reduced neuronal death in adult rat ischemic brain injury. It was reported that carvacrol blocked TRPM7 and attenuated brain injury in an adult rat MCAO model. The effects of carvacrol on neonatal stroke remain unknown. This study investigated the effects of carvacrol on neuronal injury and behavioral impairment after hypoxia-ischemia in neonatal mice and the potential signaling pathway underlying these effects. Carvacrol inhibited TRPM7 current in HEK293 cells over-expressing TRPM7 and TRPM7-like current in hippocampal neurons in a dose-dependent manner. Carvacrol (>200 μM) reduced OGD-induced neuronal injury in cortical neurons. 24 hours after HI, TRPM7 protein level in the ipsilateral hemisphere was significantly higher than in the contralateral hemisphere. Carvacrol (30 and 50 mg/kg) pre-treatment reduced brain infarct volume 24 hours after HI in a dose-dependent manner. Carvacrol pre-treatment also improved neurobehavioral outcomes. Furthermore, animals pre-treated with carvacrol had fewer TUNEL-positive cells in the brain compared to vehicle-treated animals 3 days after HI. Carvacrol pre-treatment also increased Bcl-2/Bax and p-Akt/t-Akt protein ratios and decreased cleaved caspase-3 protein expression 24 hours after HI. Carvacrol pre-treatment protects against neonatal hypoxic-ischemic brain injury by reducing brain infarct volume, promoting pro-survival signaling and inhibiting pro-apoptotic signaling, as well as improving behavioral outcomes. The neuroprotective effect may be mediated by the inhibition of TRPM7 channel function. Carvacrol is a potential drug development target for the treatment of neonatal stroke.

5 November 2012 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
HSHong-Shuo Sun
Hong-Shuo Sun
ZFZhong-Ping Feng
Zhong-Ping Feng

9 June 2021 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
DJDelphine Ji
Delphine Ji
ZLZheng-Wei Luo
Zheng-Wei Luo
AOAndrea Ovcjak
Andrea Ovcjak
RARahmah Alanazi
Rahmah Alanazi
MBMei-Hua Bao
Mei-Hua Bao
HSHong-Shuo Sun
Hong-Shuo Sun

19 April 2018 in Acta Pharmacologica Sinica
Verified
Journal Article
Open access
PDF file
VSVivian Szeto
Vivian Szeto
NCNai-Hong Chen
Nai-Hong Chen
HSHong-Shuo Sun
Hong-Shuo Sun
ZFZhong-Ping Feng
Zhong-Ping Feng
ATP-sensitive potassium (KATP) channels are ubiquitously expressed on the plasma membrane of cells in multiple organs, including the heart, pancreas and brain. KATP channels play important roles in controlling and regulating cellular functions in response to metabolic state, which are inhibited by ATP and activated by Mg-ADP, allowing the cell to couple cellular metabolic state (ATP/ADP ratio) to electrical activity of the cell membrane. KATP channels mediate insulin secretion in pancreatic islet beta cells, and controlling vascular tone. Under pathophysiological conditions, KATP channels play cytoprotective role in cardiac myocytes and neurons during ischemia and/or hypoxia. KATP channel is a hetero-octameric complex, consisting of four pore-forming Kir6.x and four regulatory sulfonylurea receptor SURx subunits. These subunits are differentially expressed in various cell types, thus determining the sensitivity of the cells to specific channel modifiers. Sulfonylurea class of antidiabetic drugs blocks KATP channels, which are neuroprotective in stroke, can be one of the high stoke risk factors for diabetic patients. In this review, we discussed the potential effects of KATP channel blockers when used under pathological conditions related to diabetics and cerebral ischemic stroke.